Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys di David D. Waters, MD

Testo

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials di Liffert Vogt, Sripal Bangalore, Rana Fayyad, Shari Melamed, G. Kees Hovingh, David A. DeMicco, David D. Waters

Testo

The association between lipid levels and leukocyte count: A cross-sectional and longitudinal analysis of three large cohorts di Sonia Sawant, Bradley Tucker, Praween Senanayake, David D. Waters, Sanjay Patel, Kerry-Anne Rye, Kwok Leung Ong, Blake J. Cochran

Testo

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin di Kwok Leung Ong, David D. Waters, Rana Fayyad, Liffert Vogt, Shari Melamed, David A. DeMicco, Kerry‐Anne Rye, Philip J. Barter

Testo

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. di Benoit J Arsenault, Philip Barter, David A DeMicco, Weihang Bao, Gregory M Preston, John C LaRosa, Scott M Grundy, Prakash Deedwania, Heiner Greten, Nanette K Wenger, James Shepherd, David D Waters, John J P Kastelein, Treating to New Targets (TNT) Investigators

Testo